Signal transduction and apoptosis pathways as therapeutic targets.
Valerón
P F
PF
Instituto de Investigaciones Biomédicas, CSIC, Arturo Duperier 4, 28029 Madrid, Spain.
Aznar-Benitah
S
S
Lacal
J C
JC
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000502:physiology*; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D019908:Proto-Oncogene Proteins c-raf / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D020703:ras GTPase-Activating Proteins / Q000378:metabolism; D020741:rho GTP-Binding Proteins / Q000378:metabolism
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D020703:ras GTPase-Activating Proteins; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor; D016044:Fusion Proteins, bcr-abl; D019908:Proto-Oncogene Proteins c-raf; D018844:Cyclin-Dependent Kinases; D020741:rho GTP-Binding Proteins